Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | F7 | P08709 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | BMX | P51813 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27231711 | 1.00 | F2 (0.36) | F2KDM4CF10F12PRSS1 | |
| SCHEMBL30749373 | 0.89 | ALDH1A1 (0.47) | F2F10F12PRSS1PRSS2 | |
| SCHEMBL27224167 | 0.85 | F2 (0.37) | F2KDM4CF10F12PRSS1 | |
| SCHEMBL27224146 | 0.76 | CPT1A (0.34) | ALDH1A1 | |
| SCHEMBL27231643 | 0.76 | CPT1A (0.34) | ALDH1A1 | |
| SCHEMBL30749212 | 0.76 | ALDH1A1 (0.40) | F2F10F12PRSS1PRSS2 | |
| SCHEMBL27224136 | 0.76 | ALDH1A1 (0.40) | F2F10F12PRSS1PRSS2 | |
| SCHEMBL27223536 | 0.74 | F2 (0.40) | F2ALDH1A1 | |
| SCHEMBL27223533 | 0.73 | F2 (0.41) | F2KDM4CALDH1A1 | |
| SCHEMBL27223609 | 0.72 | MPO (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-05-23 | — | — | US | disclosed |
| WO-2024038131-A1 | INHIBITORS OF MYELOPEROXIDASE | ASTRAZENECA AB (SE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166642-A1 | INHIBITORS OF MYELOPEROXIDASE | MPO, XDH, EPX | F2 73/4885KDM4C 3056/4885F10 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.